Exact Mass: 475.0702

Exact Mass Matches: 475.0702

Found 20 metabolites which its exact mass value is equals to given mass value 475.0702, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

   
   

Dermatan, 4-(hydrogen sulfate)

Dermatan, 4-(hydrogen sulfate)

C14H21NO15S-2 (475.0632)


B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents D006401 - Hematologic Agents > D000925 - Anticoagulants

   

Chondroitin 4-sulfate anion

Chondroitin 4-sulfate anion

C14H21NO15S-2 (475.0632)


   

alpha-L-iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine

alpha-L-iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine

C14H21NO15S-2 (475.0632)


   
   

chondroitin sulfate C anion

chondroitin sulfate C anion

C14H21NO15S-2 (475.0632)


   

Dermatan 6-sulfate anion

Dermatan 6-sulfate anion

C14H21NO15S-2 (475.0632)


   

Delta(4)-beta-D-GlcpA-(1->4)-alpha-D-GlcpNAc6S

Delta(4)-beta-D-GlcpA-(1->4)-alpha-D-GlcpNAc6S

C14H21NO15S (475.0632)


   

Delta(4)-beta-D-GlcpA-(1->3)-D-GalpNAc4S

Delta(4)-beta-D-GlcpA-(1->3)-D-GalpNAc4S

C14H21NO15S (475.0632)


   

Delta(4)-beta-D-GlcpA-(1->4)-D-GlcpNAc6S

Delta(4)-beta-D-GlcpA-(1->4)-D-GlcpNAc6S

C14H21NO15S (475.0632)


   

Delta(4)-beta-D-GlcpA2S-(1->3)-alpha-D-GlcpNAc

Delta(4)-beta-D-GlcpA2S-(1->3)-alpha-D-GlcpNAc

C14H21NO15S (475.0632)


   

alpha-L-threo-hex-4-enopyranuronosyl-(1->3)-beta-D-GalpNAc6S

alpha-L-threo-hex-4-enopyranuronosyl-(1->3)-beta-D-GalpNAc6S

C14H21NO15S (475.0632)


   

2-(Acetylamino)-4-O-[(4,5-didehydro-2-O-sulfo-1-deoxy-beta-D-glucopyranuronic acid)-1-yl]-2-deoxy-D-glucopyranose

2-(Acetylamino)-4-O-[(4,5-didehydro-2-O-sulfo-1-deoxy-beta-D-glucopyranuronic acid)-1-yl]-2-deoxy-D-glucopyranose

C14H21NO15S (475.0632)


   

Delta(4)-beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S

Delta(4)-beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S

C14H21NO15S (475.0632)


   

(2R,3R,4R)-2-[(3R,4R,5R,6R)-3-Acetamido-2,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

(2R,3R,4R)-2-[(3R,4R,5R,6R)-3-Acetamido-2,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

C14H21NO15S (475.0632)


   

(2S,3R,4R)-2-[(2R,3S,4R,5R,6R)-5-Acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

(2S,3R,4R)-2-[(2R,3S,4R,5R,6R)-5-Acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

C14H21NO15S (475.0632)


   

KCC009

KCC009

C21H22BrN3O5 (475.0743)


KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].

   

1'-[(2s,3r,4s,5s,6r)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]-5,5'-dichloro-3'-hydroxy-[2,2'-biindol]-3-one

1'-[(2s,3r,4s,5s,6r)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]-5,5'-dichloro-3'-hydroxy-[2,2'-biindol]-3-one

C22H19Cl2N3O5 (475.0702)


   

1'-(5-amino-3,4-dihydroxy-6-methyloxan-2-yl)-5,5'-dichloro-3'-hydroxy-[2,2'-biindol]-3-one

1'-(5-amino-3,4-dihydroxy-6-methyloxan-2-yl)-5,5'-dichloro-3'-hydroxy-[2,2'-biindol]-3-one

C22H19Cl2N3O5 (475.0702)